Skip to content
BOLUS

Signal from the log

ViferaXS

€12 Million · Series A · Germany · Biotech

ViferaXS développe CLLTAXS01, une immunothérapie du cancer à base de peptides qui active les lymphocytes T cytotoxiques contre des antigènes tumoraux. Le programme principal entre en phase II dans la leucémie lymphoïde chronique, avec des phases I en cours dans la leucémie aiguë myéloïde et le carcinome fibrolamellaire. Le communiqué annonce une série A « jusqu'à 12 millions d'euros, dotation comprise » : c'est un plafond et non un montant levé, et Bolus n'affiche donc aucun chiffre tant que la part en capital n'est pas publiée.

Spotted Amount read from the headline

Announced on , logged by the watch of 23 September 2026.

Operation
Funding round
Announced amount
€12 Million
Stage
Series A
Country
Germany
Sector
Biotech

What the log says

Editorial note, in French

Repérée par la collecte. Personne ne l'a encore instruite.

The investors

Led by SPRIND , Huma

What is missing before publishing
  • The amount shown is an automatic reading of the source headline, not a reading of the press release. It is not verified yet.
Provenance
Source prnewswire
Logged on 23 September 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification The fields shown come from an automatic reading of the source headline. They have not yet been checked against the press release and should not be quoted as verified.
What this status means
Spotted The collection saw this operation and logged it. Nobody has processed it yet, so what is shown is still an automatic reading of the source headline.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.

One address, nothing else.

One letter a week, on Fridays: the week's funding rounds, the funds named, the amounts double checked. The list is never sold, one click to unsubscribe. The letter is written in French.

Email confirmation before any subscription. The list is never sold. What Bolus knows about you is written on the privacy page (in French).